;
Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • ABT-450 plus ritonavir/ombitasvir: Phase II/III data

    Enanta Pharmaceuticals Inc. (NASDAQ:ENTA), Watertown, Mass. AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: ABT-450 plus ritonavir/ombitasvir (ABT-267)/dasabuvir (ABT-333) (3 direct-acting-antiviral (3D) regimen) …

    Published on 11/17/2014
  • ACH-3102: Additional Phase II data

    Achillion Pharmaceuticals Inc. (NASDAQ:ACHN), New Haven, Conn. Product: ACH-3102 Business: Infectious Molecular target: HCV NS5A protein Description: Pan-genotypic, second-generation HCV NS5A protein inhibitor …

    Published on 11/17/2014
  • AKB-6548: Phase II data

    Akebia Therapeutics Inc. (NASDAQ:AKBA), Cambridge, Mass. Product: AKB-6548 Business: Hematology Molecular target: Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) (EGLN) Description: Oral hypoxia-inducible factor …

    Published on 11/17/2014
  • Arzerra ofatumumab: Additional Phase III data

    Genmab A/S (CSE:GEN; OTCBB:GMXAY), Copenhagen, Denmark GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Arzerra ofatumumab (HuMax-CD20) Business: Cancer Molecular target: CD20 Description: Human mAb …

    Published on 11/17/2014
  • Belviq lorcaserin: Phase II data

    Arena Pharmaceuticals Inc. (NASDAQ:ARNA), San Diego, Calif. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Ildong Pharmaceutical Co. Ltd. (KSE:000230), Seoul, South Korea Product: Belviq lorcaserin (APD356) Business: …

    Published on 11/17/2014
  • Belviq lorcaserin: Phase IV data

    Arena Pharmaceuticals Inc. (NASDAQ:ARNA), San Diego, Calif. Ildong Pharmaceutical Co. Ltd. (KSE:000230), Seoul, South Korea Product: Belviq lorcaserin (APD356) Business: Endocrine/Metabolic Molecular target: Serotonin (…

    Published on 11/17/2014
  • BMS-906024: Interim Phase I data

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: BMS-906024 Business: Cancer Molecular target: Gamma secretase Description: Gamma secretase inhibitor with anti-notch activity Indication: Treat relapsed or …

    Published on 11/17/2014
  • Brodalumab: Phase III data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Brodalumab (KHK4827) (formerly AMG 827) Business: …

    Published on 11/17/2014
  • Doravirine: Additional Phase IIb data

    Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Doravirine (MK-1439) Business: Infectious Molecular target: HIV reverse transcriptase Description: Non-nucleoside HIV reverse transcriptase inhibitor (NNRTI…

    Published on 11/17/2014
  • Dupilumab: Interim Phase IIb data

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Dupilumab (REGN668, SAR231893) Business: Inflammation Molecular target: Interleukin-4 (IL-4) receptor…

    Published on 11/17/2014
  • Grazoprevir/elbasvir: Interim Phase II data

    Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Grazoprevir/elbasvir (MK-5172/MK-8742) Business: Infectious Molecular target: HCV NS3/4A protease complex; HCV NS5A protein Description: Fixed-dose oral …

    Published on 11/17/2014
  • Keytruda pembrolizumab: Preliminary Phase Ib data

    Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Keytruda pembrolizumab (MK-3475) (formerly lambrolizumab) Business: Cancer Molecular target: Programmed cell death 1 (PDCD1) (PD-1) (CD279) Description: …

    Published on 11/17/2014
  • MOR00208: Phase II data

    MorphoSys AG (Xetra:MOR; Pink:MPSYF), Martinsried, Germany Xencor Inc. (NASDAQ:XNCR), Monrovia, Calif. Product: MOR00208, MOR208 (formerly XmAb5574) Business: Cancer Molecular target: CD19 Description: Fc-optimized …

    Published on 11/17/2014
  • Oral neratinib: Phase II data

    Puma Biotechnology Inc. (NYSE:PBYI), Los Angeles, Calif. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Oral neratinib (HKI-272, PB272) Business: Cancer Molecular target: Epidermal growth factor receptor 1 (EGFR1) (…

    Published on 11/17/2014
  • OTX-DP dexamethasone-loaded punctum plug: Phase II data

    Ocular Therapeutix Inc. (NASDAQ:OCUL), Bedford, Mass. Product: OTX-DP dexamethasone-loaded punctum plug Business: Inflammation Molecular target: NA Description: Hydrogel-based punctum plug that delivers sustained- and …

    Published on 11/17/2014
  • Revusiran: Phase II data

    Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Cambridge, Mass. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Revusiran (SAR438714, ALN-TTRsc) Business: Endocrine/Metabolic Molecular target: Transthyretin (TTR) …

    Published on 11/17/2014
  • SAGE-547: Additional Phase I/II data

    Sage Therapeutics Inc. (NASDAQ:SAGE), Cambridge, Mass. Product: SAGE-547 Business: Neurology Molecular target: GABA A receptor Description: Positive allosteric modulator (PAM) of GABA A receptor Indication: Treat super-…

    Published on 11/17/2014
  • Ulocuplumab: Phase I data

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: Ulocuplumab (BMS-936564) (formerly MDX-1338) Business: Cancer Molecular target: CXC chemokine receptor 4 (CXCR4) (NPY3R) Description: Human IgG4 mAb against …

    Published on 11/17/2014
  • VB-111: Additional Phase I/II data

    VBL Therapeutics Ltd. (NASDAQ:VBLT), Or Yehuda, Israel Product: VB-111 Business: Cancer Molecular target: NA Description: Dual anti-angiogenic and vascular disruptive agent (VDA) using Vascular Targeting System (VTS) …

    Published on 11/17/2014
  • ADXS-HPV: Preliminary Phase I/II data

    Advaxis Inc. (NASDAQ:ADXS), Princeton, N.J. Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India Product: ADXS-HPV (ADXS11-001) (formerly Lovaxin C) Business: Cancer Molecular target: Not applicable Description: Live …

    Published on 11/10/2014
  • AG014: Phase I data

    ActoGeniX N.V., Zwijnaarde, Belgium Product: AG014 Business: Autoimmune Molecular target: Tumor necrosis factor (TNF) alpha Description: Lactococcus lactis ActoBiotic genetically modified to express and secrete an anti-…

    Published on 11/10/2014
  • AMAP102: Phase IIa data

    AnaMar AB, Gothenburg, Sweden Product: AMAP102 Business: Autoimmune Molecular target: Serotonin (5-HT2B) receptor Description: Serotonin (5-HT2B) receptor antagonist Indication: Treat mild to moderate osteoarthritis (OA…

    Published on 11/10/2014
  • Ampion: Additional Phase I data

    Ampio Pharmaceuticals Inc. (NYSE-M:AMPE), Englewood, Colo. Product: Ampion Business: Autoimmune Molecular target: NMDA receptor; Serotonin (5-HT2C) receptor Description: A cyclic aspartate-alanine dipeptide cleaved from…

    Published on 11/10/2014
  • AVI-7100: Phase I data

    Sarepta Therapeutics Inc. (NASDAQ:SRPT), Cambridge, Mass. Product: AVI-7100 Business: Infectious Molecular target: NA Description: RNA-based influenza therapeutic based on phosphorodiamidate morpholino oligomer (PMO) …

    Published on 11/10/2014
  • Dabrafenib: Additional Phase III data

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Dabrafenib (Tafinlar) (GSK2118436) Business: Cancer Molecular target: BRAF Description: Oral BRAF protein kinase inhibitor Indication: Treat advanced or …

    Published on 11/10/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993